TY - JOUR T1 - Monoclonal antibodies for treating COVID-19 JF - Cleveland Clinic Journal of Medicine JO - Cleve Clin J Med DO - 10.3949/ccjm.88a.ccc074 AU - Andrea M. Pallotta AU - ChungYun Kim AU - Steven M. Gordon AU - Alice Kim Y1 - 2021/02/17 UR - http://www.ccjm.org/content/early/2021/02/17/ccjm.88a.ccc074.abstract N2 - Bamlanivimab and casirivimab-imdevimab are novel virus-neutralizing monoclonal antibodies authorized to treat mild to moderate COVID-19 in outpatients at risk for progression to severe disease. Treatment early in the disease may show efficacy in reducing progression to severe disease, although safety and efficacy data are limited. They are not authorized for hospitalized patients with more advanced disease. ER -